Register
Febuxostat and allopurinol similar in terms of cardiovascular outcomes |
Journal Updates
eMediNexus Coverage from: 
Febuxostat and allopurinol similar in terms of cardiovascular outcomes
eMediNexus,  13 March 2018
remove_red_eye 780 Views
#Cardiology #Internal Medicine #Pathology and Lab Medicine #Pharmacist #Rheumatology

1 Read Comments                

Febuxostat was similar to allopurinol with respect to rates of adverse cardiovascular events in patients with gout and major cardiovascular coexisting conditions, according to the CARES trial published March 12, 2018 in the New England Journal of Medicine. However, all-cause mortality and cardiovascular mortality were higher with febuxostat.


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.


  • Dr sharat samantray 14 March - 08:36 hrs

    A good learning point from the prestigious journal.

    • REPLY